Spire Healthcare Group (LON:SPI) Given New GBX 280 Price Target at JPMorgan Chase & Co.

Spire Healthcare Group (LON:SPI) had its price objective hoisted by JPMorgan Chase & Co. from GBX 249 ($3.12) to GBX 280 ($3.50) in a report issued on Friday, Marketbeat reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 26.41% from the company’s previous close.

Separately, Barclays lifted their price objective on Spire Healthcare Group from GBX 300 ($3.75) to GBX 305 ($3.82) and gave the stock an “overweight” rating in a research report on Friday.

Spire Healthcare Group Stock Performance

Shares of Spire Healthcare Group stock opened at GBX 221.50 ($2.77) on Friday. Spire Healthcare Group has a one year low of GBX 202 ($2.53) and a one year high of GBX 252.50 ($3.16). The company has a market cap of £895.13 million, a price-to-earnings ratio of 11,075.00, a PEG ratio of 1.06 and a beta of 1.15. The company has a debt-to-equity ratio of 164.23, a quick ratio of 0.74 and a current ratio of 0.78. The business’s 50 day moving average price is GBX 216.44 and its 200 day moving average price is GBX 219.98.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.